Nova Leap Health (NLH) AI Stock Analysis

• Market Cap: C$26.19M
• Dividend Yield: N/A
• Average Volume (3M): 21.45K
• Price to Earnings (P/E): 157.9
• Beta (1Y): 0.58
• Revenue Growth: 19.61%
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): <0.01
• Shares Outstanding: 87,314,255
• 10 Day Avg. Volume: 17,344
• 30 Day Avg. Volume: 21,452
• PEG Ratio: -0.05
• Price to Book (P/B): 0.90
• Price to Sales (P/S): 0.64
• P/FCF Ratio: 12.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: C$0.37 ▲(21.67% Upside)

Nova Leap Health's stock score is primarily driven by its improved profitability and strong technical indicators, despite challenges in revenue growth and cash flow. The stock's high valuation and lack of dividend yield are notable concerns.

Positive Factors

Profitability Improvement

The shift to positive net income indicates improved profitability, which enhances financial stability and supports future growth initiatives.

Strong Equity Position

A strong equity position with low leverage provides financial flexibility and reduces risk, supporting long-term operational resilience.

Positive Free Cash Flow

Positive free cash flow indicates effective cash management, enabling reinvestment in business expansion and debt reduction.

Negative Factors

Revenue Decline

The decline in revenue suggests challenges in market expansion or service demand, which could impact long-term growth prospects.

Decreased Operating Cash Flow

Reduced operating cash flow may limit the company's ability to fund operations and invest in growth, potentially affecting future performance.

Revenue Growth Challenges

Continued challenges in revenue growth could hinder the company's ability to scale and compete effectively in the healthcare sector.

Nova Leap Health Business Overview & Revenue Model

Company Description

Nova Leap Health (NLH) is a leading provider of home health care services, primarily focused on delivering personalized in-home support for seniors and individuals with disabilities. The company operates in the healthcare sector, offering a range of services including personal care, companionship, and respite care. NLH's mission is to enhance the quality of life for its clients while providing peace of mind to their families through compassionate and reliable care.

How the Company Makes Money

Nova Leap Health generates revenue through its home health care services by charging clients for the hours of care provided. The company typically operates on a fee-for-service model, where clients are billed based on the specific services rendered. Key revenue streams include personal care services, which may involve assistance with daily living activities, and specialized care for clients with specific health needs. NLH also benefits from partnerships with healthcare providers and insurance companies, which can facilitate client referrals and enhance service offerings. Additionally, the company may explore opportunities for government contracts or funding programs aimed at supporting home health care services, contributing further to its earnings.

Nova Leap Health Financial Statement Overview

Summary

Nova Leap Health shows improved profitability with a positive net income in 2024 and a strong equity position. However, revenue has declined, and cash flow from operations has decreased, indicating challenges in revenue growth and cash generation.

Income Statement

Nova Leap Health has demonstrated fluctuations in revenue with a notable decline from $28.2M in 2022 to $25.8M in 2024. Gross profit margin has remained relatively stable, yet net income turned positive in 2024 at $1.38M from a loss in previous years, indicating improved profitability. EBIT and EBITDA margins are positive but show room for enhancement, highlighting potential operational efficiency improvements.

Balance Sheet

The company maintains a healthy equity base with an equity ratio of approximately 81.5% in 2024. The debt-to-equity ratio is relatively low at 0.14, suggesting manageable leverage. Return on equity improved significantly in 2024, reflecting enhanced profitability and effective use of equity.

Cash Flow

Operating cash flow decreased to $1.39M in 2024 from $2.15M in 2023, reflecting potential challenges in cash generation from operations. However, the company maintains positive free cash flow. The operating cash flow to net income ratio is strong at 1.01, indicating efficient conversion of income to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.11M	25.76M	26.18M	28.21M	21.28M	17.31M
Gross Profit	11.00M	9.89M	9.77M	9.98M	7.21M	5.87M
EBITDA	1.23M	2.50M	994.47K	420.35K	4.76M	2.36M
Net Income	116.09K	1.38M	-1.05M	-835.75K	1.76M	1.26M
Balance Sheet
Total Assets	23.59M	22.39M	20.90M	23.95M	26.77M	17.54M
Cash, Cash Equivalents and Short-Term Investments	1.39M	1.40M	894.76K	1.27M	1.73M	2.78M
Total Debt	3.27M	2.53M	1.40M	3.97M	6.20M	5.96M
Total Liabilities	4.93M	4.14M	2.70M	5.27M	8.29M	7.69M
Stockholders Equity	18.66M	18.25M	18.20M	18.68M	18.48M	9.84M
Cash Flow
Free Cash Flow	1.41M	1.36M	2.13M	949.49K	2.18M	3.01M
Operating Cash Flow	1.43M	1.39M	2.15M	1.02M	2.18M	3.01M
Investing Cash Flow	-2.58M	-1.59M	-23.13K	-56.24K	-7.40M	-1.56M
Financing Cash Flow	1.37M	729.78K	-2.52M	-1.41M	4.33M	-325.46K

Nova Leap Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.30
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NLH, the sentiment is Negative. The current price of 0.3 is below the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.30, and above the 200-day MA of 0.27, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 49.72 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NLH.

Nova Leap Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NLH	68 Neutral	C$26.19M	157.89	4.10%	―	19.61%	―
CRRX	52 Neutral	C$229.69M	3,650.00	0.11%	0.56%	0.19%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHA	42 Neutral	C$1.39M	-0.12	-1473.72%	―	-22.61%	7.72%
NUMI	41 Neutral	C$13.86M	-0.45	―	―	―	―
JNH	34 Underperform	$413.49K	―	―	―	―	―

Nova Leap Health Corporate Events

Nova Leap Health Corp. Achieves Record Q3 2025 Financial Performance

Nova Leap Health Corp. announced record-breaking financial results for Q3 2025, marking the best performance in the company’s history. The company achieved record consolidated revenues, gross margin, and Adjusted EBITDA across its Canadian and U.S. operating segments. With a 3% increase in revenues from the previous quarter and a significant improvement in net income, Nova Leap demonstrates strong operational discipline and growth potential. The company’s robust financial performance is supported by a strong balance sheet and access to acquisition financing, positioning it well for future expansion and value creation.

The most recent analyst rating on (TSE:NLH) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Nova Leap Health stock, see the TSE:NLH Stock Forecast page.

Nova Leap Health Corp. Achieves Record Q3 2025 Financial Results

Nova Leap Health Corp. announced record-breaking financial results for Q3 2025, marking the best performance in the company’s history. The company achieved record consolidated revenues, gross margins, and Adjusted EBITDA across its Canadian and U.S. segments. The strong financial performance is attributed to consistent execution and operational discipline, with significant improvements in net income and operating cash flow. The company maintains a robust balance sheet with substantial credit available for future acquisitions, supporting its long-term growth strategy.

The most recent analyst rating on (TSE:NLH) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Nova Leap Health stock, see the TSE:NLH Stock Forecast page.